SOAT1 and COVID-19: In a study conducted on COVID-19, it was reported that Ruxolitinib exhibited therapeutic effects by inhibiting the JAK/STAT pathway in the treatment of pulmonary inflammation characterized by cytokine release syndrome (La Rosée et al. 2020).